Welcome to our dedicated page for Picard Medical news (Ticker: PMI), a resource for investors and traders seeking the latest updates and insights on Picard Medical stock.
Picard Medical, Inc. (NYSE American: PMI) is the parent company of SynCardia Systems, LLC, a medical technology company focused on total artificial heart therapy for patients with advanced and end-stage heart failure. News about Picard Medical often centers on the SynCardia Total Artificial Heart (STAH), which company materials describe as the only commercially available total artificial heart technology for patients with end-stage heart failure and the first artificial heart approved by both the U.S. Food and Drug Administration (FDA) and Health Canada.
Readers of this PMI news page can expect coverage of clinical and technology milestones related to the SynCardia Total Artificial Heart and the next-generation, fully implantable Emperor Total Artificial Heart platform. Recent company announcements have highlighted in vitro and in vivo data on the Emperor system, including the first pre-clinical implantations of the fully implantable device, as well as presentations at specialized heart failure and mechanical circulatory support conferences.
Picard Medical’s news flow also includes updates on product enhancements, such as the rollout of FDA-cleared CPC1 Connector Covers designed to provide additional protection and comfort for patients using the SynCardia Total Artificial Heart. Corporate and capital markets developments, including senior secured debt financings, registration statements, and participation in healthcare investor conferences, are disclosed through press releases and corresponding SEC filings.
Investors and clinicians following PMI news can use this page to review company communications on regulatory developments, collaboration agreements for the Emperor platform, clinical data presentations, and broader strategic updates related to total artificial heart technology. The news archive offers a consolidated view of how Picard Medical and SynCardia are advancing their artificial heart platforms and engaging with the heart failure and medical device communities.
Picard Medical (NYSE American: PMI) reported second quarter 2026 revenue of approximately $3.0 million, up 39% from about $2.1 million a year earlier, driven by higher U.S. sales. Gross profit was roughly $0.6 million versus a gross loss of about $0.1 million, with gross margin improving to ~20.9% from ~(6.0)%. Net loss decreased 16% to around $5.7 million from approximately $6.7 million.
For the first six months of 2026, revenue rose 50% to roughly $4.1 million, with gross profit of about $0.9 million and gross margin of ~21.7% compared with a ~(17.7)% gross margin in 2025. Year-to-date net loss increased to approximately $13.3 million, mainly due to higher research and development and selling, general and administrative expenses. The company advanced preclinical work on its next-generation Emperor Total Artificial Heart, presented new clinical and engineering data, and continued manufacturing efficiency initiatives. NYSE American accepted its compliance plan, and a 1-for-50 reverse stock split became effective on July 31, 2026.
Picard Medical (NYSE American: PMI), parent of SynCardia, announced a key milestone for its Emperor Total Artificial Heart (Emperor TAH) program with the first public scientific presentation of the integrated Emperor TAH architecture at IEEE EMBC 2026 in Toronto.
The poster detailed how the patent-pending Emperor Drive System (EDS), a compact electromechanical driver, integrates with the clinically proven SynCardia Total Artificial Heart ventricles. According to the company, the architecture preserves existing blood-contacting components used in more than 2,100 patients while introducing next-generation drive technology designed to support future advances in mobility, quality of life, and potential full implantability.
Picard Medical (NYSE American: PMI), parent of SynCardia Systems, announced that Taha Hasekioglu, Director, Office of the COO & Emperor Program Lead, will present engineering insights on the next-generation Emperor Total Artificial Heart (Emperor TAH) at IEEE EMBC 2026 in Toronto.
The Emperor TAH combines SynCardia Total Artificial Heart ventricles with Picard Medical’s new electromechanical Emperor Drive System (EDS). This poster presentation, scheduled for July 29, 2026, 4:30–6:30 PM EDT in Hall E (Theme 6: Wearable Biomedical Sensors and Systems), will be the first public scientific introduction of the Emperor Drive System architecture and will outline its preliminary electromechanical design and integration. Picard Medical expects to release further technical details after the conference.
Picard Medical (NYSE American: PMI), parent of SynCardia Systems, announced that NYSE American has accepted its plan to regain compliance with continued listing standards under Sections 1003(a)(i) and (ii) of the NYSE American Company Guide.
The acceptance allows Picard Medical’s common stock to continue trading on NYSE American while the company executes operational, strategic, and financial initiatives in its plan. Picard Medical has been granted a compliance period through November 8, 2027, subject to periodic exchange review and adherence to other listing standards, and it plans to keep advancing its total artificial heart platforms and long-term growth strategy.
Picard Medical (NYSE American: PMI) will implement a 1-for-50 reverse stock split of its issued and outstanding common stock to support continued compliance with NYSE American listing standards. The board approved the split after stockholders authorized a reverse split range of 1-for-15 to 1-for-50 on July 17, 2026.
The reverse split is expected to become effective at 5:00 p.m. ET on July 31, 2026, with PMI shares trading on a split-adjusted basis starting August 3, 2026 under the same ticker and a new CUSIP 71953R 207. Outstanding shares and related equity instruments will be proportionately adjusted, with fractional shares rounded up to the nearest whole share.
Picard Medical (NYSE American: PMI), parent of SynCardia, announced publication of an independent commentary in peer-reviewed journal Artificial Organs on its next-generation Emperor total artificial heart platform, which integrates the Emperor Drive with the SynCardia Total Artificial Heart.
The article reviews total artificial heart history and recent preclinical large-animal implants of the “Emperor TAH.” According to Picard Medical, three acute implants were completed successfully, delivering stable full circulatory support with physiologic autoregulation and no device-related intraoperative failures. The commentary highlights the platform’s independent dual-motor design for separate systemic and pulmonary control and its potential to more closely replicate cardiac function without an external pneumatic driver. It also notes SynCardia’s two decades of clinical experience and that its Total Artificial Heart is the only commercially available device of this type approved in the U.S. and Canada. The publication states the piece is a news update and not an endorsement.
Picard Medical (NYSE American: PMI), parent of SynCardia, released a pre-recorded stockholder presentation ahead of its virtual 2026 Annual Meeting on July 17, 2026. The presentation reviews recent business performance, including an 85% year-over-year revenue increase for the first three months of 2026, driven by a 116% rise in U.S. revenue, and a gross margin of 24% versus -4% in 2025.
Picard Medical outlines manufacturing optimization efforts and development of its next-generation Emperor platform, which replaces the external pneumatic driver with an electromechanical actuation system and targets a fully implantable total artificial heart. Milestones include pursuit of FDA Breakthrough Device designation, continued preclinical studies, a planned IDE submission in 2028, and intended clinical study activities in 2029.
The presentation also summarizes proposals for stockholder vote: election of directors, amendments to the capital structure, auditor ratification, and advisory votes on executive compensation. Stockholders of record may vote online, by phone, or during the virtual meeting.
Picard Medical (NYSE American: PMI), parent of SynCardia, released a pre-recorded presentation ahead of its July 17, 2026 annual stockholder meeting.
The presentation reviews Q1 revenue up 85% year-over-year, U.S. revenue up 116%, gross margin at 28%, manufacturing optimization, Emperor platform development milestones, and key voting proposals, including director elections and capital structure amendments.
Picard Medical (NYSE American: PMI), parent of SynCardia Systems, announced a leadership transition. Patrick NJ Schnegelsberg stepped down as CEO and director effective June 18, 2026, with no disagreement cited regarding company operations or policies.
The Board appointed Executive Chairman Richard Fang, Ph.D. as Interim CEO while it searches for a permanent chief. Fang will retain his chairman role and brings over 20 years of medical device experience, including founding and expanding Reach Surgical and leading it through a sale.
SynCardia continues as maker of the world’s first total artificial heart approved by both the FDA and Health Canada, with an ongoing mission to support patients with advanced biventricular heart failure and its clinical partners.
Picard Medical (NYSE American: PMI), parent of SynCardia, will present new in vivo data on its next-generation Emperor Total Artificial Heart and new patient outcome research on the SynCardia Total Artificial Heart at the ASAIO 2026 conference in New Orleans, June 18–21, 2026.
Talks cover hemodynamic performance of the fully implantable Emperor platform and a holistic analysis of survival, recovery, transplantability, and quality of life for SynCardia Total Artificial Heart patients.